Physician profile
Candice Baldeo
NPI 1518300557
$20,520.68
in general payments reported to CMS, 2019-2025
52 companies · $2,438 in 2025
The $2,438 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,447 · 2020: $2,016 · 2021: $7,081 · 2022: $6,390 · 2024: $149 · 2025: $2,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,100 · Food and Beverage: $443 · Education: $44.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,100.00 |
| Food and Beverage | $442.75 |
| Education | $44.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $5,098.98 | 2021-2022 | |
| Glaxosmithkline, LLC. | $2,750.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $2,745.00 | 2019-2024 | Calquence |
| Abbvie INC. | $2,372.33 | 2019-2025 | |
| Amgen INC. | $905.05 | 2019-2022 | |
| Daiichi Sankyo INC. | $684.41 | 2019-2025 | Vanflyta |
| Genentech USA, INC. | $587.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $573.90 | 2019-2024 | Keytruda |
| Seagen INC. | $511.38 | 2019-2022 | |
| Janssen Biotech, INC. | $393.28 | 2019-2021 | |
| Celgene Corporation | $389.74 | 2019-2021 | |
| Pfizer INC. | $353.03 | 2019-2022 | |
| Lilly USA, LLC | $349.39 | 2019-2024 | |
| Genzyme Corporation | $323.12 | 2019-2022 | |
| Eisai INC. | $257.79 | 2020-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Baldeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.